- Home
- SIEB vs HLVX Comparison
SIEB vs HLVX Comparison
Compare SIEB & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIEB
- HLVX
- Stock Information
- Founded
- SIEB 1886
- HLVX 2020
- Country
- SIEB United States
- HLVX United States
- Employees
- SIEB N/A
- HLVX N/A
- Industry
- SIEB Investment Bankers/Brokers/Service
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- SIEB Finance
- HLVX Health Care
- Exchange
- SIEB Nasdaq
- HLVX Nasdaq
- Market Cap
- SIEB 110.4M
- HLVX 104.3M
- IPO Year
- SIEB N/A
- HLVX 2022
- Fundamental
- Price
- SIEB $2.93
- HLVX $2.09
- Analyst Decision
- SIEB
- HLVX Hold
- Analyst Count
- SIEB 0
- HLVX 1
- Target Price
- SIEB N/A
- HLVX $2.00
- AVG Volume (30 Days)
- SIEB 67.2K
- HLVX 796.3K
- Earning Date
- SIEB 11-11-2025
- HLVX 11-06-2025
- Dividend Yield
- SIEB N/A
- HLVX N/A
- EPS Growth
- SIEB N/A
- HLVX N/A
- EPS
- SIEB 0.24
- HLVX N/A
- Revenue
- SIEB $86,037,000.00
- HLVX N/A
- Revenue This Year
- SIEB N/A
- HLVX N/A
- Revenue Next Year
- SIEB N/A
- HLVX N/A
- P/E Ratio
- SIEB $11.88
- HLVX N/A
- Revenue Growth
- SIEB 9.07
- HLVX N/A
- 52 Week Low
- SIEB $1.87
- HLVX $1.34
- 52 Week High
- SIEB $5.77
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- SIEB 46.04
- HLVX 51.68
- Support Level
- SIEB $2.48
- HLVX $2.07
- Resistance Level
- SIEB $2.63
- HLVX $2.11
- Average True Range (ATR)
- SIEB 0.18
- HLVX 0.03
- MACD
- SIEB 0.06
- HLVX -0.00
- Stochastic Oscillator
- SIEB 82.26
- HLVX 33.33
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.